Från wikipedia:
Recipharm AB is a Swedish company, active as a pharmaceutical contract development and manufacturing organization(CDMO), with production facilities in Sweden, France, the UK and Switzerland and a development site in Sweden. Its current production consists of over six hundred different products in a variety of dosage forms to global pharmaceutical companies. History
1995 - The company Recip was founded, by the owners Lars Backsell and Thomas Eldered, after a Management Buyout of a tablet production site owned by Pharmacia. Recip at this stage had 140 employees an 220 million SEK turnover.
1998 - Recip’s first CMO commissions for two major Nordic pharmaceutical companies. Tricum Fibres site in Höganäs, Sweden, was acquired.
2001 - The CMO brand Recipharm was established.
2002 - A penicillin plant in Strängnäs, Sweden, was acquired from AstraZeneca.
2004 - A semi solid facility in Karlskoga, Sweden, was acquired from AstraZeneca.
2005 - The organisation was restructured into separate subsidiaries.
2007 - A final decision was made, to focus only on outsourcing business. The distribution company with the Recip products was sold to Meda. A sterile facility was acquired in Monts, France, from AstraZeneca. A new development centre was obtained. A “multi-purpose” facility was acquired in Great Britain.
2008 - Acquisition of: Lyophilisation facility in Switzerland, A capsule production facility in Fontaine-lès-Dijon, France, The majority share of an AstraZeneca biotech laboratory in Södertälje, Sweden. About 1400 employees, turnover 1427 million SEK. The name of the company was changed from Recip to Recipharm.
